Brief: Elicera Therapeutics Provides Update On CARMA Study
06/03/2026 08:00
March 6 (Reuters) - Elicera Therapeutics AB ELIC.ST: COMPLETE METABOLIC RESPONSE (CMR) AND WELL TOLERATED TREATMENT IN FIRST TWO PATIENTS OF COHORT 3 IN CARMA STUDY ACROSS 8 PATIENTS TREATED TO DATE: DISEASE CONTROL RATE: 100%, OVERALL RESPONSE RATE (ORR): 7/8, CMR AT MONTH 1: 6/8 Source text: ID:nWkr5RDLt4 Further company coverage: ELIC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent